Literature DB >> 25357119

A Study of the Frequency and Social Determinants of Exposure to Cancer-Related Direct-to-Consumer Advertising Among Breast, Prostate, and Colorectal Cancer Patients.

Andy S L Tan1.   

Abstract

Cancer-related direct-to-consumer advertising (DTCA) is controversial because cancer treatment is complex and entails more risks and costs than typical treatments that are advertised for other conditions. Drawing from the Structural Influence Model of Communication, this study explores communication inequalities in DTCA exposure across social determinants among a population-based sample of 2013 patients diagnosed with breast, prostate, or colorectal cancers. Three survey items assessed patients' frequency of encountering ads concerning treatment alternatives for cancer, dealing with side effects of treatment, and doctors or hospitals offering services for cancer following their diagnosis. The analysis showed that overall exposure to DTCA in this study population was modest (median was once per week). Breast cancer patients reported significantly higher exposure to all three ad categories and overall DTCA exposure than prostate and colorectal cancer patients. Older patients consistently reported lower overall exposure to DTCA across the three cancer types. Other significant correlates included ethnicity (higher exposures among African American prostate cancer patients vs. White; lower exposures in Hispanic colorectal cancer patients vs. White) and cancer stage (higher exposures in Stage IV prostate cancer patients vs. Stages 0-II). Education level did not predict patients' DTCA exposure. The implications of these observed inequalities in DTCA exposure on cancer outcomes are discussed.

Entities:  

Mesh:

Year:  2014        PMID: 25357119      PMCID: PMC4416102          DOI: 10.1080/10410236.2014.921752

Source DB:  PubMed          Journal:  Health Commun        ISSN: 1041-0236


  30 in total

Review 1.  Direct-to-consumer prescription drug advertising: trends, impact, and implications.

Authors:  M S Wilkes; R A Bell; R L Kravitz
Journal:  Health Aff (Millwood)       Date:  2000 Mar-Apr       Impact factor: 6.301

2.  DTC advertising's programmatic research and its effect on health communication.

Authors:  Richard F Beltramini
Journal:  Health Commun       Date:  2010-09

3.  Comprehension of information in three direct-to-consumer television prescription drug advertisements among adults with limited literacy.

Authors:  Kimberly A Kaphingst; Rima E Rudd; William Dejong; Lawren H Daltroy
Journal:  J Health Commun       Date:  2005 Oct-Nov

4.  Advertising, patient decision making, and self-referral for computed tomographic and magnetic resonance imaging.

Authors:  Judy Illes; Dylan Kann; Kim Karetsky; Phillip Letourneau; Thomas A Raffin; Pamela Schraedley-Desmond; Barbara A Koenig; Scott W Atlas
Journal:  Arch Intern Med       Date:  2004 Dec 13-27

5.  Update on Direct-to-Consumer Marketing in Oncology.

Authors:  Stacy W Gray; Gregory A Abel
Journal:  J Oncol Pract       Date:  2012-02-21       Impact factor: 3.840

6.  Direct-to-consumer prescription drug advertising, 1989-1998. A content analysis of conditions, targets, inducements, and appeals.

Authors:  R A Bell; R L Kravitz; M S Wilkes
Journal:  J Fam Pract       Date:  2000-04       Impact factor: 0.493

7.  Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States.

Authors:  Kathryn E Weaver; Julia H Rowland; Keith M Bellizzi; Noreen M Aziz
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

8.  Response rates to a mailed survey of a representative sample of cancer patients randomly drawn from the Pennsylvania Cancer Registry: a randomized trial of incentive and length effects.

Authors:  Bridget J Kelly; Taressa K Fraze; Robert C Hornik
Journal:  BMC Med Res Methodol       Date:  2010-07-14       Impact factor: 4.615

9.  Direct-to-consumer advertising: public perceptions of its effects on health behaviors, health care, and the doctor-patient relationship.

Authors:  Elizabeth Murray; Bernard Lo; Lance Pollack; Karen Donelan; Ken Lee
Journal:  J Am Board Fam Pract       Date:  2004 Jan-Feb

10.  Promotion of prescription drugs to consumers and providers, 2001-2010.

Authors:  Rachel Kornfield; Julie Donohue; Ernst R Berndt; G Caleb Alexander
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more
  1 in total

1.  Determinants of the Cancer Drug Funding Process in Canada.

Authors:  Joanna Gotfrit; Ashley Jackson; John J W Shin; David J Stewart; Ranjeeta Mallick; Paul Wheatley-Price
Journal:  Curr Oncol       Date:  2022-03-15       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.